

**NSABP Protocol B-14: Characteristics of Patients
for whom TMA Material is Available for Study**

	Placebo	Tamoxifen	Registered	All
	No. (%)	No. (%)	No. (%)	No. (%)
Age				
<=49	102 (30.5)	75 (29.4)	108 (32.0)	285 (30.8)
50-59	111 (33.2)	76 (29.8)	84 (24.9)	271 (29.3)
>=60	121 (36.2)	104 (40.8)	145 (43.0)	370 (40.0)
Race				
White	301 (90.1)	238 (93.3)	307 (91.1)	846 (91.4)
Black	14 (4.2)	10 (3.9)	18 (5.3)	42 (4.5)
Other	16 (4.8)	5 (2.0)	7 (2.1)	28 (3.0)
Unknown	3 (0.9)	2 (0.8)	5 (1.5)	10 (1.1)
Clinical Tumor Size (cm)				
<=2.0	173 (51.8)	136 (53.3)	215 (63.8)	524 (56.6)
2.1-4.0	141 (42.2)	103 (40.4)	106 (31.5)	350 (37.8)
>=4.1	20 (6.0)	16 (6.3)	16 (4.7)	52 (5.6)
Type of Surgery				
Mastectomy	215 (64.4)	137 (53.7)	211 (62.6)	563 (60.8)
Lumpectomy	119 (35.6)	118 (46.3)	126 (37.4)	363 (39.2)
Estrogen Receptor (fmol)				
10-49	147 (44.0)	92 (36.1)	130 (38.6)	369 (39.8)
50-99	54 (16.2)	56 (22.0)	73 (21.7)	183 (19.8)
100+	133 (39.8)	107 (42.0)	134 (39.8)	374 (40.4)
Disease-free Survival				
Alive, Event-free	121 (36.2)	112 (43.9)	178 (52.8)	411 (44.4)
Experienced an Event	213 (63.8)	143 (56.1)	159 (47.2)	515 (55.6)
Total Person Months of Follow-up for Events	47,366.5	39,752.4	53,321.8	140,440.7
Overall Survival				
Alive	184 (55.1)	145 (56.9)	231 (68.5)	560 (60.5)
Dead	150 (44.9)	110 (43.1)	106 (31.5)	366 (39.5)
Total Person Months of Follow-up for Deaths	61,492.6	46,377.9	60,932.6	168,803.1
All	334 (100.0)	255 (100.0)	337 (100.0)	926 (100.0)